R A Hauser

Summary

Affiliation: University of South Florida
Country: USA

Publications

  1. ncbi request reprint Parkinson's disease home diary: further validation and implications for clinical trials
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa, Florida, USA
    Mov Disord 19:1409-13. 2004
  2. ncbi request reprint Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
    Robert A Hauser
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida 33606, USA
    Mov Disord 22:2409-17. 2007
  3. ncbi request reprint Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD
    Robert A Hauser
    Department of Neurology, University of South Florida, and Tampa General Healthcare, 33606, USA
    Neurology 61:297-303. 2003
  4. ncbi request reprint Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa, FL 33606, USA
    Arch Neurol 63:1756-60. 2006
  5. ncbi request reprint Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease
    Robert A Hauser
    Department of Neurology, University of South Florida and Tampa General Healthcare, Tampa, Florida 33606, USA
    Mov Disord 17:961-8. 2002
  6. ncbi request reprint Advances in the pharmacologic management of early Parkinson disease
    Robert A Hauser
    Department of Neurology, Parkinson s Disease and Movement Disorders Center, University of South Florida and Tampa General Healthcare, Tampa, Florida 33606, USA
    Neurologist 13:126-32. 2007
  7. ncbi request reprint Bilateral human fetal striatal transplantation in Huntington's disease
    R A Hauser
    Department of Neurology, University of South Florida, Tampa, FL 33606, USA
    Neurology 58:687-95. 2002
  8. doi request reprint Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease
    R A Hauser
    University of South Florida, Tampa, FL 33606, USA
    Eur Neurol 62:40-8. 2009
  9. ncbi request reprint Clinical trials aimed at detecting neuroprotection in Parkinson's disease
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa General Healthcare, Tampa, Florida, USA
    Neurology 66:S58-68. 2006
  10. ncbi request reprint Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease
    Robert A Hauser
    Department of Neurology, University of South Florida and Tampa General Healthcare, NPF Center of Excellence, Tampa, Florida 33606, USA
    Mov Disord 22:359-65. 2007

Research Grants

Collaborators

Detail Information

Publications89

  1. ncbi request reprint Parkinson's disease home diary: further validation and implications for clinical trials
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa, Florida, USA
    Mov Disord 19:1409-13. 2004
    ..Good on time (ONG = on time without dyskinesia or with nontroublesome dyskinesia) most strongly correlated with patients' perceived duration of a good response through the day and is an important outcome variable...
  2. ncbi request reprint Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
    Robert A Hauser
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida 33606, USA
    Mov Disord 22:2409-17. 2007
    ..Early treatment decisions for individual patients depend largely on the anticipated risk of side effects and long-term complications. Both ropinirole and levodopa are viable treatment options in early PD...
  3. ncbi request reprint Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD
    Robert A Hauser
    Department of Neurology, University of South Florida, and Tampa General Healthcare, 33606, USA
    Neurology 61:297-303. 2003
    ..To evaluate the safety and efficacy of the adenosine A(2A) receptor antagonist istradefylline (KW-6002) in patients with levodopa-treated Parkinson's disease (PD) with both motor fluctuations and peak-dose dyskinesias...
  4. ncbi request reprint Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa, FL 33606, USA
    Arch Neurol 63:1756-60. 2006
    ..Motor fluctuations and dyskinesias can cause disability and reduce quality of life for patients with Parkinson disease (PD)...
  5. ncbi request reprint Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease
    Robert A Hauser
    Department of Neurology, University of South Florida and Tampa General Healthcare, Tampa, Florida 33606, USA
    Mov Disord 17:961-8. 2002
    ....
  6. ncbi request reprint Advances in the pharmacologic management of early Parkinson disease
    Robert A Hauser
    Department of Neurology, Parkinson s Disease and Movement Disorders Center, University of South Florida and Tampa General Healthcare, Tampa, Florida 33606, USA
    Neurologist 13:126-32. 2007
    ..However, the disease continues to progress, and the long-term use of levodopa is associated with the development of motor fluctuations and dyskinesias...
  7. ncbi request reprint Bilateral human fetal striatal transplantation in Huntington's disease
    R A Hauser
    Department of Neurology, University of South Florida, Tampa, FL 33606, USA
    Neurology 58:687-95. 2002
    ..Transplanted striatal cells have been demonstrated to survive, grow, establish afferent and efferent connections, and improve behavioral signs in animal models of Huntington's disease (HD)...
  8. doi request reprint Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease
    R A Hauser
    University of South Florida, Tampa, FL 33606, USA
    Eur Neurol 62:40-8. 2009
    ..To investigate the safety and tolerability of pardoprunox (SLV308), a novel partial dopamine agonist, as an adjunct to levodopa in patients with advanced Parkinson's disease, using two titration schedules...
  9. ncbi request reprint Clinical trials aimed at detecting neuroprotection in Parkinson's disease
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa General Healthcare, Tampa, Florida, USA
    Neurology 66:S58-68. 2006
    ..Better methods of assessing putative neuroprotection in PD are needed...
  10. ncbi request reprint Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease
    Robert A Hauser
    Department of Neurology, University of South Florida and Tampa General Healthcare, NPF Center of Excellence, Tampa, Florida 33606, USA
    Mov Disord 22:359-65. 2007
    ....
  11. ncbi request reprint Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson disease
    Robert A Hauser
    Parkinson s Disease and Movement Disorders Center, University of South Florida and Tampa General Healthcare, Tampa, FL 33606, USA
    Clin Neuropharmacol 29:322-30. 2006
    ....
  12. ncbi request reprint Future therapies for Parkinson's disease
    Robert A Hauser
    Department of Neurology, University of South Florida and Tampa General Healthcare, Tampa, FL 33606, USA
    Neurol Clin 22:S149-66. 2004
  13. ncbi request reprint Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience
    Robert A Hauser
    Department of Neurology, University of South Florida and Tampa General Healthcare, Tampa, Florida 33606, USA
    Drugs Aging 22:471-82. 2005
    ..Additional studies are necessary to evaluate the benefit of istradefylline as monotherapy in early disease, its effect on the development of dyskinesia, and its effect on disease progression...
  14. ncbi request reprint Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease
    Ray L Watts
    Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama 35294 0017, USA
    Mov Disord 25:858-66. 2010
    ..Ropinirole prolonged-release delayed the onset of dyskinesia with comparable efficacy to increased doses of levodopa in early PD patients not optimally controlled with levodopa...
  15. ncbi request reprint Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments
    Elmyra V Encarnacion
    Department of Neurology, Texas A and M Health Sciences Center, Scott and White National Parkinson Foundation Plummer Movement Disorders Center, Temple, TX, USA
    Eur Neurol 60:57-66. 2008
    ..Several new compounds that may provide an antidyskinetic effect are also under investigation...
  16. doi request reprint Treatment of early Parkinson's disease. Part 2
    Tanya Simuni
    Department of Neurology, Northwestern University, Parkinson s Disease and Movement Disorders Center, Chicago, Ill, USA
    Eur Neurol 61:206-15. 2009
    ..Part 2 of the article, presented here, reviews key data relevant to the assessment of potential neuroprotective therapies and the treatment of non-motor symptoms...
  17. ncbi request reprint Long-term efficacy of rasagiline in early Parkinson's disease
    Mark F Lew
    Department of Neurology, Keck University of Southern California School of Medicine, Los Angeles, California 90033, USA
    Int J Neurosci 120:404-8. 2010
    ..Rasagiline was well tolerated, with 11.3% of patients (45/398) withdrawing because of an adverse event. Rasagiline therapy for PD was effective, well tolerated, and safe in this long-term trial...
  18. ncbi request reprint Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias
    Robert A Hauser
    Parkinson s Disease and Movement Disorders Center, National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, FL, USA
    Geriatrics 61:14-20. 2006
    ..Treatments that reduce motor complications, allowing a higher level of functioning, lessen the burden of care in long-term care settings and increase quality of life for patients and their families...
  19. doi request reprint Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial
    H H Fernandez
    Department of Neurology, University of Florida Movement Disorders Center, PO Box 100236, 100 South Newell Dr, L3 100, Gainesville, FL 32610 0236, USA
    Parkinsonism Relat Disord 16:16-20. 2010
    ..6002-US-051 was a 12-week, double-blind study evaluating the safety and efficacy of istradefylline, a selective A(2A) adenosine receptor antagonist, as monotherapy in patients with Parkinson's disease (PD)...
  20. pmc Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology
    T B Freeman
    Department of Neurosurgery, Department of Pharmacology and Experimental Therapeutics, and the Neuroscience Program, University of South Florida, Tampa, FL 33606, USA
    Proc Natl Acad Sci U S A 97:13877-82. 2000
    ..This study demonstrates that grafts derived from human fetal striatal tissue can survive, develop, and are unaffected by the disease process, at least for 18 months, after transplantation into a patient with HD...
  21. ncbi request reprint Levodopa/carbidopa/entacapone (Stalevo)
    Robert A Hauser
    Department of Neurology, University of South Florida and Tampa General Healthcare, Tampa, Florida 33606, USA
    Neurology 62:S64-71. 2004
    ....
  22. doi request reprint Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours
    Joseph H Friedman
    Department of Neurology, Alpert School of Medicine, Brown University, Providence, Rhode Island 02906, USA
    Int J Neurosci 121:472-6. 2011
    ..This report is a compilation of vignettes describing these behavioral problems that the treating neurologist or psychiatrist attributed to the medications used for treating PD...
  23. ncbi request reprint Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations
    Bonnie P Hersh
    Department of Neurology, Harvard Vanguard Medical Associates, Boston, Massachusetts 02215, USA
    Mov Disord 25:927-31. 2010
    ..1; 95%CI, -1.7, -0.5; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once-daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation...
  24. ncbi request reprint Ropinirole therapy for Parkinson's disease
    Rajesh Pahwa
    Department of Neurology, University of Kansas Medical Center, 3599 Rainbow Blvd, Kansas City, KS 66160, USA
    Expert Rev Neurother 4:581-8. 2004
    ..A once-daily formulation of ropinirole is currently in development that has the potential for greater convenience, improved tolerability and greater efficacy...
  25. doi request reprint Treatment of early Parkinson's disease. Part 1
    Tanya Simuni
    Department of Neurology, Northwestern University, Parkinson s Disease and Movement Disorders Center, Chicago, Ill 60611, USA
    Eur Neurol 61:193-205. 2009
    ..Safety and tolerability data are also reviewed. Part 2 of the article reviews key findings relevant to the assessment of potential neuroprotective therapies and the treatment of non-motor symptoms...
  26. ncbi request reprint Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study
    Cheryl H Waters
    Department of Neurology, Columbia University, New York, New York 10032, USA
    Mov Disord 19:426-32. 2004
    ..Adverse events were consistent with known effects of levodopa therapy. Zydis selegiline safely reduces daily off time when used as adjunctive therapy with levodopa in patients with PD...
  27. ncbi request reprint Social Security Disability Insurance (SSDI) in Parkinson's disease
    T A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, FL 33612, USA
    Disabil Rehabil 29:1934-6. 2007
    ..We performed a descriptive pilot study that examined PD patients' experience with SSDI...
  28. ncbi request reprint Ropinirole for restless legs syndrome: a placebo-controlled crossover trial
    C H Adler
    Parkinson s Disease and Movement Disorders Center, Mayo Clinic Scottsdale, AZ 85259, USA
    Neurology 62:1405-7. 2004
    ..Eight of the 22 patients had complete resolution of symptoms on ropinirole. Adverse events included nausea and dizziness. Ropinirole was effective and well tolerated for treating the symptoms of RLS...
  29. ncbi request reprint Heart failure in Parkinson's disease: analysis of the United States medicare current beneficiary survey
    T A Zesiewicz
    Department of Neurology, University of South Florida, 12901 Bruce B Downs Blvd MDC 55, Tampa, FL 33612, USA
    Parkinsonism Relat Disord 10:417-20. 2004
    ..We sought to examine the prevalence of heart failure in elderly PD versus non-PD patients using a national sample of Medicare beneficiaries in the United States...
  30. ncbi request reprint Neurosurgery for Parkinson's disease
    T A Zesiewicz
    Parkinson's Disease and Movement Disorders Center, Department of Neurology, University of South Florida, Tampa 33606, USA
    Semin Neurol 21:91-101. 2001
    ..This chapter reviews the history of surgical procedures for PD, describes current procedures, and offers a look into the future of neurosurgical options for PD...
  31. ncbi request reprint Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa, Florida 33606, USA
    Mov Disord 25:2542-9. 2010
    ..Pramipexole ER administered once daily was demonstrated to be efficacious compared with placebo and provided similar efficacy and tolerability as pramipexole IR administered TID...
  32. ncbi request reprint Nonmotor symptoms of Parkinson's disease
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center and Department of Neurology, University of South Florida, 12901 Bruce B Downs Blvd, MDC Box 55, Tampa, FL 33612, USA
    Expert Rev Neurother 6:1811-22. 2006
    ..A new screening questionnaire and the revised Unified PD Rating Scale should assist healthcare providers to better identify and evaluate these symptoms. This article reviews the identification and treatment of nonmotor symptoms in PD...
  33. ncbi request reprint Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
    Robert A Hauser
    University of South Florida, Tampa, FL, USA
    Lancet Neurol 10:221-9. 2011
    ..We aimed to assess the efficacy and safety of preladenant in patients with Parkinson's disease and motor fluctuations who were receiving levodopa and other antiparkinsonian drugs...
  34. ncbi request reprint A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida 33612, USA
    Mov Disord 22:279-82. 2007
    ..ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry...
  35. ncbi request reprint Pregabalin (Lyrica) in the treatment of essential tremor
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, Neuroscience Program, University of South Florida, Tampa, Florida 33612, USA
    Mov Disord 22:139-41. 2007
    ..Both patients also reported moderate reduction in tremor on the Clinical Global Impression Scale, and Fahn-Tolosa-Marin Part I scores were markedly improved...
  36. ncbi request reprint A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida 33612, USA
    Mov Disord 22:1660-3. 2007
    ..PGB provided significant improvements in accelerometry and in action tremor limb scores on the FTM. However, larger studies are needed to further evaluate the potential effect of PGB on ET...
  37. ncbi request reprint Early pharmacologic treatment in Parkinson's disease
    Robert A Hauser
    USF Health Movement Disorders Center, 5 Tampa General Circle, Harbourside Medical Tower, Tampa, FL 33606, USA
    Am J Manag Care 16:S100-7. 2010
    ..Physicians should also consider the early use of MAO-B inhibitors in light of their very good tolerability and the recent evidence suggesting long-term disease-modifying effects...
  38. doi request reprint Levodopa: past, present, and future
    Robert A Hauser
    Departments of Neurology, Molecular Pharmacology, and Physiology, University of South Florida, Tampa, FL 33606, USA
    Eur Neurol 62:1-8. 2009
    ..Attempts are underway to develop oral and transdermal very long-acting levodopa preparations...
  39. doi request reprint Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease
    Robert A Hauser
    Parkinsons s Disease and Movement Disorders Center, University of South Florida, 5 Tampa General Circle, Tampa, FL 33606, USA
    Mov Disord 24:564-73. 2009
    ..This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD...
  40. doi request reprint Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease
    Robert A Hauser
    Parkinson s Disease and Movement Disorders Center of Excellence, University of South Florida, 4 Columbia Drive, Suite 410, Tampa, FL 33606, USA
    Mov Disord 24:541-50. 2009
    ..3%) subjects in the LCE group and 16 (7.4%) in the LC group (P = 0.367). Nausea and diarrhea were reported more frequently in the LCE group. LCE provided greater symptomatic benefit than LC and did not increase motor complications...
  41. doi request reprint Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa, Florida 33606, USA
    Mov Disord 23:2177-85. 2008
    ..We conclude that istradefylline is well tolerated and significantly reduces OFF time as an adjunct to levodopa in PD subjects with motor fluctuations...
  42. doi request reprint Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, University of South Florida, Tampa, 33612, USA
    Clin Neuropharmacol 32:48-50. 2009
    ..The severe bradykinesia and rigidity persisted despite reactivation of the deep brain stimulator and immediate reinstitution of Parkinson disease medications, but resolved completely several hours after discontinuation of fentanyl...
  43. ncbi request reprint Chorea as a side effect of gabapentin (Neurontin) in a patient with complex regional pain syndrome Type 1
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, NPF Center of Excellence, University of South Florida, Tampa, FL, USA
    Clin Rheumatol 27:389-90. 2008
    ..The chorea lasted for a year and resolved completely within 2 weeks of discontinuing gabapentin...
  44. doi request reprint Levodopa response in early Parkinson's disease
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa, Florida 33606, USA
    Mov Disord 24:2328-36. 2009
    ..A substantial proportion of subjects with early PD did not experience a robust response to levodopa. An improvement in UPDRSm of approximately 22% best discriminated levodopa treatment from placebo...
  45. doi request reprint Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa, Florida 33606, USA
    Mov Disord 24:979-83. 2009
    ..54). Glutathione was well tolerated and no safety concerns were identified. Preliminary efficacy data suggest the possibility of a mild symptomatic effect, but this remains to be evaluated in a larger study...
  46. ncbi request reprint Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida 33612, USA
    Curr Neurol Neurosci Rep 7:302-10. 2007
    ..Deep brain stimulation of the subthalamic nucleus is now the most commonly used surgical procedure for PD patients, and it is very effective in treating LID...
  47. ncbi request reprint Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida 33612, USA
    Mov Disord 21:1998-2001. 2006
    ..6 +/- 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop-out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients...
  48. ncbi request reprint Essential tremor. Epidemiology, diagnosis, and treatment
    Kelly L Sullivan
    Department of Neurology, Parkinson s Disease and Movement Disorders Center, Tampa General Hospital Healthcare, University of South Florida, Tampa, Florida 33612, USA
    Neurologist 10:250-8. 2004
    ..Symptoms are typically progressive and potentially disabling, often forcing patients to change jobs or seek early retirement. Proper treatment is contingent on a correct diagnosis, and other possible causes of tremor must be excluded...
  49. ncbi request reprint Substantial improvement in a Meige's syndrome patient with levetiracetam treatment
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA
    Mov Disord 19:1518-21. 2004
    ..This report and data from an animal model of paroxysmal dystonia suggest that LEV might be helpful in the treatment of dystonia...
  50. ncbi request reprint Levetiracetam-induced parkinsonism in a Huntington disease patient
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, NPF Centers of Experience, Department of Neurology, University of South Florida Tampa, Florida 33612, USA
    Clin Neuropharmacol 28:188-90. 2005
    ..Symptoms consisted of resting tremor, rigidity, increased dystonia, and gait difficulty. Side effects from levetiracetam resolved completely within 7 days of levetiracetam discontinuation, and chorea returned to baseline...
  51. ncbi request reprint Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease
    Kelly L Sullivan
    Parkinson s Disease and Movement Disorders Center, NPF Center of Excellence, University of South Florida, Tampa, Florida 33612, USA
    Mov Disord 21:115-6. 2006
    ..There was a trend for improvement in the Subject's Global Assessment (SGA) of satisfaction with bowel habits (NS) and the total SGA (including abdominal discomfort, bothersome constipation, and satisfaction; NS)...
  52. ncbi request reprint Translocation breakpoint in two unrelated Tourette syndrome cases, within a region previously linked to the disorder
    Fiona C Crawford
    Department of Psychiatry, University of South Florida, 3515 E Fletcher Avenue, Tampa, FL 33613, USA
    Hum Genet 113:154-61. 2003
    ....
  53. ncbi request reprint Clozapine withdrawal symptoms in a Parkinson's disease patient
    Theresa A Zesiewicz
    Department of Neurology, Parkinson s Disease and Movement Disorders Center, University of South Florida and Tampa General Healthcare, Tampa, Florida 33606, USA
    Mov Disord 17:1365-7. 2002
    ..Clozapine should be gradually withdrawn over a period of 1 to 2 weeks when possible, and abruptly discontinued only when necessary...
  54. ncbi request reprint Long-term evaluation of deep brain stimulation of the thalamus
    Rajesh Pahwa
    Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas 66160, USA
    J Neurosurg 104:506-12. 2006
    ..The aim of this study was to evaluate the long-term safety and efficacy of DBS of the ventralis intermedius nucleus (VIM) of the thalamus for PD and ET...
  55. ncbi request reprint Management of essential tremor
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Harborside Medical Tower, 4 Columbia Drive, Suite 410, Tampa, FL 33606, USA
    Curr Neurol Neurosci Rep 2:324-30. 2002
    ..In patients with medically refractory tremor, alternative therapies, including surgery or injections of botulinum toxin, may be considered...
  56. ncbi request reprint Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida 336112, USA
    Mov Disord 20:1205-9. 2005
    ..There was a 56% dropout rate, mostly due to somnolence. In PD patients who experienced peak-dose dyskinesia for at least 25% of the awake day, LEV significantly improved on time without dyskinesia or with nontroublesome dyskinesia...
  57. ncbi request reprint Topiramate-induced psychosis in patients with essential tremor: report of 2 cases
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, 33612, USA
    Clin Neuropharmacol 29:168-9. 2006
    ..All adverse symptoms resolved several days after topiramate was discontinued...
  58. ncbi request reprint The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, 33612, USA
    Clin Neuropharmacol 29:106-11. 2006
    ..In patients with low or low-normal folate levels, levodopa administration is associated with a greater increase in homocysteine and concomitant entacapone administration is associated with a greater reduction in homocysteine...
  59. ncbi request reprint Depression in Parkinson's disease
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida College of Medicine, 4 Columbia Drive, Suite 410, Tampa, FL 33606, USA
    Curr Psychiatry Rep 4:69-73. 2002
    ..This information may help guide clinical treatment and define the need for further studies...
  60. ncbi request reprint Neural transplantation in Parkinson's disease
    T B Freeman
    Department of Neurosurgery, University of South Florida, College of Medicine, Tampa, Florida 33606, USA
    Adv Neurol 86:435-45. 2001
    ..There are numerous ways to improve current techniques of neural transplantation...
  61. ncbi request reprint Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology
    T A Zesiewicz
    Department of Neurology, Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, USA
    Neurology 64:2008-20. 2005
    ....
  62. ncbi request reprint Driving safety in Parkinson's disease
    T A Zesiewicz
    Department of Neurology, University of South Florida, Tampa, USA
    Neurology 59:1787-8. 2002
    ..7, p < 0.01). In PD patients, collisions were associated with Hoehn and Yahr stage (chi(2) = 12.4, p = 0.006) and correlated with Unified Parkinson's Disease Rating Scale score (r = 0.5, p < 0.01)...
  63. doi request reprint A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Mov Disord 23:2194-201. 2008
    ..We here describe the rationale for the study and baseline characteristics of the 1,176 patients who have been enrolled into the trial...
  64. ncbi request reprint Chorea in a patient with cerebral palsy: treatment with levetiracetam
    Maria V Recio
    Department of Neurology, University of South Florida, Tampa, FL 33612, USA
    Mov Disord 20:762-4. 2005
    ..We report on the case of an adult cerebral palsy patient who developed severe chorea coincident with a febrile illness from a nonstreptococcal infection. The chorea improved markedly with the use of levetiracetam (LEV, Keppra)...
  65. doi request reprint New considerations in the medical management of early Parkinson's disease: impact of recent clinical trials on treatment strategy
    Robert A Hauser
    University of South Florida, Department of Neurology, Tampa, FL 33606, USA
    Parkinsonism Relat Disord 15:S17-21. 2009
    ..The current approach to treatment of early PD depends in part on individual patient factors including age, severity of motor signs, presence of cognitive dysfunction, and other co-morbidities...
  66. ncbi request reprint Deep brain stimulation of the internal segment of the globus pallidus in delayed runaway dyskinesia
    John Graff-Radford
    Department of Neurology, University of Florida Movement Disorders Center, University of Florida, Gainesville, FL, USA
    Arch Neurol 63:1181-4. 2006
    ....
  67. ncbi request reprint Sleep attacks and dopamine agonists for Parkinson's disease: what is currently known?
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa General Healthcare, Tampa, Florida 33606, USA
    CNS Drugs 17:593-600. 2003
    ..Patients with Parkinson's disease and caregivers should be informed about the risk of sleepiness and sleep attacks associated with dopaminergic medications and the potential implications for driving safety...
  68. ncbi request reprint Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease
    M Gold
    University of South Florida College of Medicine, Department of Neurology, Tampa 33612, USA
    Metab Brain Dis 13:43-53. 1998
    ..These results suggest that plasma thiamine deficiency is associated with pAD but not with iPD...
  69. ncbi request reprint Phenomenology and treatment of tremor disorders
    T A Zesiewicz
    Parkinson's Disease and Movement Disorders Center, Department of Neurology, Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA
    Neurol Clin 19:651-80, vii. 2001
    ..Accurate diagnosis is a critical factor in predicting the natural history and response to treatment...
  70. ncbi request reprint Levetiracetam for the treatment of generalized dystonia
    Kelly L Sullivan
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, FL 33612, USA
    Parkinsonism Relat Disord 11:469-71. 2005
    ..Improvements were noted in blepharospasm, cervical, and truncal dystonia. The patient has been on LEV for a total of 20 weeks, and has experienced sustained improvement of symptoms...
  71. ncbi request reprint Use of nutritional supplements in Parkinson's disease patients
    Summer C Wolfrath
    Parkinson s Disease and Movement Disorders Center, NPF Center of Excellence, and Department of Neurology, College of Medicine, University of South Florida, Tampa, Florida, USA
    Mov Disord 21:1098-101. 2006
    ..Greater awareness of nutritional supplement use in PD patients is warranted to avoid potentially harmful effects and drug interactions...
  72. doi request reprint Levetiracetam for stiff-person syndrome: report of 2 patients
    W Reed Shimberg
    Parkinson s Disease and Movement Disorders Center, NPF Center of Excellence, Tampa, Florida, USA
    Clin Neuropharmacol 31:301-2. 2008
    ..We report 2 patients with stiff-person syndrome whose spasms were greatly relieved by levetiracetam (Keppra)...
  73. ncbi request reprint Tiagabine and exacerbation of essential tremor
    Theresa A Zesiewicz
    Mov Disord 22:2132-3. 2007
  74. ncbi request reprint Treatment of chorea with levetiracetam
    Theresa A Zesiewicz
    Eur J Clin Pharmacol 62:87. 2006
  75. ncbi request reprint Vascular hemichorea/hemiballismus and topiramate
    Theresa A Zesiewicz
    Mov Disord 21:581; author reply 582. 2006
  76. ncbi request reprint Bilateral human fetal striatal transplantation in Huntington's disease
    Robert A Hauser
    Neurology 58:1704; author reply 1704. 2002
  77. ncbi request reprint Duodenal levodopa infusion for the treatment of Parkinson's disease
    Johan Samanta
    University of Arizona, Banner Good Samaritan Medical Center, Department of Neurology, College of Medicine, Phoenix, AZ 85258 USA
    Expert Opin Pharmacother 8:657-64. 2007
    ..This article reviews the published data describing the efficacy and safety of duodenal levodopa, and discusses its current and potential role in meeting the needs of PD patients...
  78. ncbi request reprint Chorea induced by lamotrigine
    Theresa A Zesiewicz
    J Child Neurol 21:357; author reply 357-8. 2006
  79. ncbi request reprint Role of the pharmacist in the effective management of wearing-off in Parkinson's disease
    William Simonson
    Commission for Certification in Geriatric Pharmacy
    Ann Pharmacother 41:1842-9. 2007
    ..To evaluate the role of the practicing pharmacist in the identification and current treatment of the levodopa wearing-off phenomenon experienced by patients with Parkinson's disease (PD) who are receiving chronic levodopa therapy...
  80. ncbi request reprint Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
    Alan L Whone
    Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    Ann Neurol 54:93-101. 2003
    ..1%; levodopa, -22.9%; 95% CI, 4.24-13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by (18)F-dopa PET...
  81. ncbi request reprint Levetiracetam for the treatment of essential tremor
    Kelly L Sullivan
    Mov Disord 20:640. 2005
  82. ncbi request reprint Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study
    Daniel Truong
    The Parkinson s and Movement Disorders Institute, Fountain Valley, California 92708, USA
    Mov Disord 20:783-91. 2005
    ..These results confirm previous reports that Dysport (500 units) is safe, effective, and well-tolerated in patients with cervical dystonia...
  83. doi request reprint Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease
    Jeffrey H Kordower
    Department of Neurological Sciences and Center for Brain Repair, Rush University Medical Center, 1735 West Harrison Street, Chicago, Illinois 60612, USA
    Nat Med 14:504-6. 2008
    ..These findings have implications for cell-based therapies and for understanding the cause of Parkinson's disease...
  84. ncbi request reprint Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients
    Matthew B Stern
    University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 19:916-23. 2004
    ..05, Fisher's exact test). The frequency and types of adverse events reported by rasagiline-treated and placebo-treated patients were similar. These results suggest that rasagiline monotherapy is well tolerated and efficacious in early PD...
  85. ncbi request reprint Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions
    Christopher G Goetz
    Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
    Mov Disord 23:690-9. 2008
    ..Recognition of factors that impact placebo response rates should be incorporated into individual study designs for PD clinical trials...
  86. doi request reprint Delayed thalamic intracranial hemorrhage in an essential tremor patient following deep brain stimulation
    Theresa A Zesiewicz
    Eur Neurol 59:187-9. 2008
  87. ncbi request reprint Prevalence and treatment of non-motor symptoms in Parkinson's disease
    Kelly L Sullivan
    Parkinsonism Relat Disord 13:545. 2007
  88. pmc Caffeine and progression of Parkinson disease
    David K Simon
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02115, USA
    Clin Neuropharmacol 31:189-96. 2008
    ..We assessed this relationship using data from 2 recent clinical trials of PD...
  89. ncbi request reprint Optimizing bioavailability in the treatment of Parkinson's disease
    Lauren C Seeberger
    Parkinson s Disease Institute and Movement Disorders Center, Idaho Elks Rehabilitation Hospital, 600 North Robbins Road, Boise, ID 83702, USA
    Neuropharmacology 53:791-800. 2007
    ..Considering bioavailability of a medication when prescribing drugs to treat Parkinson's disease may improve patient response and minimize adverse effects...

Research Grants3

  1. PD Neuroprotection Clinical Trial: Clinical Centers
    Robert Hauser; Fiscal Year: 2002
    ..Specific Aim II: To participate in the development of the design of the neuroprotection trial.Specific Aim III: To participate in the selection of possible neuroprotective agents to be studied. ..
  2. PD Neuroprotection Clinical Trial: Clinical Centers
    Robert Hauser; Fiscal Year: 2007
    ..Specific Aim II: To participate in the development of the design of the neuroprotection trial.Specific Aim III: To participate in the selection of possible neuroprotective agents to be studied. ..
  3. PD Neuroprotection Clinical Trial: Clinical Centers
    Robert Hauser; Fiscal Year: 2008
    ..Specific Aim II: To participate in the development of the design of the neuroprotection trial.Specific Aim III: To participate in the selection of possible neuroprotective agents to be studied. ..